Argent Biopharma Ltd · ASX:RGT
Argent Biopharma — Investor Presentation (September 2024)
26 slides from Argent Biopharma's investor presentation, Sep 6, 2024
Slide 1: A drug discovery company dedicated to addressing unmet medical needs
For personal use only A drug discovery company dedicated to addressing unmet medical needs Focusing on the Central nervous system (CNS) and Autoimmune systems September 2024 Company Presentation
Slide 2: Disclaimer
For personal use only Disclaimer The information contained in this presentation and any accompanying oral use of or reliance on information contained in this document including representations presentation (“Presentation”) is being supplied to you by Argent BioPharma on or warranties or in relation
Slide 3: Argent BioPharma is a specialized Biopharmaceutical company
Argent BioPharma is a specialized Biopharmaceutical company For personal use only focused on developing and marketing innovative drugs. Committed to providing accessible medical treatments for unmet medical needs. Innovative Technology Platform: Utilizing advanced nanotechnology and a multidisciplin
Slide 4: Argent BioPharma Vision and Mission
Argent BioPharma Vision and Mission For personal use only Vision: Argent BioPharma aspires to become a leading biopharmaceutical company recognized globally for its innovative treatments that address unmet medical needs, particularly in the central nervous system (CNS) and immune-related diseases. T
Slide 5: R&D Centers and Manufacturing Capabilities
For personal use only R&D Centers and Manufacturing Capabilities (3 sites in total) 5 Page
Slide 6: In-house Research, Development & Production
In-house Research, Development & Production For personal use only Wholly owned and Operated EU GMP Sites • Slovenia,. Emonska R&D hub is staffed with over 40 highly experienced pharmaceutical industry professionals dedicated to developing advanced drug formulations and delivery systems. • Slovenia,
Slide 7: Slovenia - EU Research and Development site
Slovenia - EU Research and For personal use only Development site Integrated research hub ensuring innovation, patient access, long-term value, and a strong market position. • Advanced R&D Operations: Operates with a team of skilled professionals, ensuring continuous innovation and progress in drug
Slide 8: Malta Manufacturing site
For personal use only Malta Manufacturing site Fully built EU GMP manufacturing facility A modern EU GMP-certified manufacturing facility, operational for less than three years and supported by multi-million dollar grants from the Maltese government1. • Automated Production Capabilities: The facil
Slide 9: Key Products
For personal use only Key Products We utilize advanced nanotechnology and a multidisciplinary approach in our in-house R&D platform to develop innovative therapies for unmet medical needs. 9 Page
Slide 10: CannEpil Refractory Epilepsy
CannEpil Epilepsy ® For personal use only Refractory Early-Stage Revenue Generating Refractory Epilepsy Seizure Control Treatment • Approximately 30% of generalized seizure epilepsy patients have Refractory Epilepsy, aka “Drug-Resistant Epilepsy" (DRE)¹, representing 15,000,000 patients around the w
Slide 11: CannEpil Refractory Epilepsy Market potential
CannEpil Epilepsy ® For personal use only Refractory Market potential 15M 150K £7000³ Worldwide UK Potential CannEpil Treatment Estimate Potential Patients with per patient per annum Patients with DRE DRE Forwards Looking: • Commercial strategy is a combination of 3rd party distribution supported by
Slide 12: CimetrA Acute Lung Injury and ARDS
CimetrA® Acute Lung Injury and ARDS Early Stage Revenue Generating For personal use only Immunomodulation Treatment for ARDS CimetrA® delivered 50,000 units to the USA market (Under Special Access) and over 100,000 worldwide, representing over US$2,500,000 in sales to date. Results of Preclinical an
Slide 13: CimetrA Market potential
CimetrA® For personal use only Acute Lung Injury and ARDS Market potential Cases of severe illness of influenza worldwide1 3-5M Per annum Respiratory deaths 290-650K Per annum Potentially, CimetrA® can be used to treat inflammatory conditions with £100B2 total addressable market. Key points • Sales
Slide 14: CogniCann Dementia and Alzheimer's
CogniCann® For personal use only Dementia and Alzheimer’s Improving quality of life in Dementia and Alzheimer’s • 55 million people worldwide suffering from Dementia and Alzheimer’s1 • CogniCann® designed as a treatment for the symptoms associated with Dementia and Alzheimer’s • Patients in the Plac
Slide 15: IrniCann Glioblastoma
IrniCann® For personal use only Glioblastoma Pre-Clinical Stage Glioblastoma • Innovative pre-clinical stage drug targeting Glioblastoma Multiforme (GBM) Stem Cells, one of the deadliest forms of brain cancer, with the potential to transform treatment outcomes for this aggressive disease • An estim
Slide 16: DerNaPol Chronic Wounds
DerNaPol Chronic Wounds For personal use only Pre-Clinical Stage for Chronic Wounds Treatment • Chronic wounds are a major global health issue, costing billions in treatment annually (e.g., £3.2 billion in the UK 1 in 2015; $28.1 to $96.8 billion in the USA in 20142). These wounds cause extreme suff
Slide 17: Research and Development Product Pipeline
Research and Development Product Pipeline For personal use only US FDA & EMA Registration Plan Actively pursuing FDA approval with potential Orphan Drug Designation. Marketing Preclinical Phase I Phase IIA Phase IIB Phase III Authorization CimetrA ® Revenue Generating Acute Lung Injury and ARDS Cann
Slide 18: Qualified team with versatile industry experience and expertise
For personal use only Qualified team with versatile industry experience and expertise 18 Page
Slide 19: Management team: Roby Zomer
Roby Roby Zomer is an accomplished executive with extensive experience in the biopharmaceutical and biotech Zomer industries. As the CEO of the company, Roby has demonstrated strong leadership in driving strategic growth, managing financial operations, and ensuring compliance with industry-specific
Slide 20: Management team: Amir Polak
Amir Amir is a seasoned professional with over 18 years of experience in the pharmaceutical and chemical Polak industries. Currently serving as the Pharmaceutical Development Officer at Argent Biopharma LTD, Amir has a strong background in strategic planning, project management, and intellectual pro
Slide 21: Medical advisors
For personal use only Medical advisors 21 Page
Slide 22: Medical advisors: Dr. Jonathan Grunfeld and Prof. Uri Kramer
Dr. Jonathan Dr. Jonathan Grunfeld is a highly experienced neurologist and neuro-oncologist with a career spanning over two Grunfeld decades. He completed his medical degree at Tel Aviv University, followed by a fellowship in neuro-oncology at the prestigious MD Anderson Cancer Center. Dr. Grunfeld
Slide 23: Financials
For personal use only Financials 1 1. 30 June 2024 Preliminary Financial Report https://www.investi.com.au/api/announcements/rgt/ba7eeb34-10e.pdf 23 Page
Slide 24: Profit and loss, balance sheet and cash flow
PROFIT AND LOSS (USD) JUN 23- JUL 24* JUN 22- JUL 23 Revenue 894,263 2,241,621 For personal use only Gross profit 315,845 959,620 Operating loss (10,957,390) (13,149,334) Loss for the year (11,523,050) (13,984,482) BALANCE SHEET (USD) JUN 23- JUL 24* JUN 22-JUL 23 Total assets 7,074,104 6,606,382 To
Slide 25: Revenues by products
For personal use only Revenues by products Sales by products (USD) JUN 23- JUL 24 JUN 22 – JUL 23 CannEpil® 436,334 860,699 CogniCann® 47,300 331,615 CimetrA® - 3,862 ArtemiC * 300,000 1,000,000 Others 110,629 45,445 SUM 894,263 2,241,621 Sales by GEO region(USD) JUN 23 – JUL 24 JUN 22 – JUL 23 Unit
Slide 26: Addresses unmet medical needs
For personal use only Addresses unmet Medical needs info@argentbiopharma.com Argent BioPharma @argentbiopharma @ArgentBioPharma Argent BioPharma Ltd.
Argent BioPharma — Investor Presentation (September 2024) on 6ix